Adjuvant imatinib after resection of gastrointestinal stromal tumour - systematic review and meta-analysis
Journal Title: OncoReview - Year 2013, Vol 3, Issue 4
Abstract
[b]Background:[/b] Adjuvant therapy is recommended for population of patients with high risk of recurrence after resection of gastrointestinal stromal tumour.[b]The aim of the study:[/b] Evaluation of clinical efficacy and safety profile of imatinib used in adjuvant therapy in patients after complete resection of gastrointestinal stromal tumour.[b]Material and methods:[/b] A systematic review of literature published up to 30.03.2012 was performed and a meta-analysis of identified studies was carried out. Databases were searched: PubMed, EMBASE, The Cochrane Library and others.[b]Results:[/b] Two randomized clinical trials regarding comparisons of: imatinib vs. placebo and 12 months of adjuvant imatinib vs. 36 months of adjuvant imatinib as well as 20 non-randomized trials fulfilled established criteria. Adjuvant imatinib statistically significantly improves recurrence-free survival compared with placebo. Patients with high risk of recurrence benefit the most from assigned treatment. Three years of adjuvant imatinib therapy improve recurrence-free and overall survival compared with 1 year of imatinib in patients after resection of gastrointestinal stromal tumour. Safety profile of imatinib in analyzed population is acceptable.[b]Conclusions:[/b] For patients with a significant risk of recurrence adjuvant therapy with imatinib should be considered to each patient, due to the clinical benefits it brings.
Authors and Affiliations
Paweł Kawalec, Joanna Kryst, Tomasz Laczewski, Lech Martyna
Keywords
Related Articles
- EP ID EP67734
- DOI -
- Views 230
- Downloads 0
Znaczenie badań molekularnych w kwalifikacji do terapii I linii erlotynibem chorych na NDRP na podstawie wyników badania EURTAC
W latach 2010–2011 pierwszy inhibitor kinazy tyrozynowej EGFR (IKT EGFR) – gefitynib uzyskał w wielu krajach rejestrację do leczenia w I linii chorych na zaawansowanego i miejscowo zaawansowanego niedrobnokomórkowego rak...
Dylematy w leczeniu raka nerki - pazopanib
Postęp w leczeniu systemowym przerzutowego raka nerki związany jest z rejestracją nowych leków. Przyniosło to poprawę wyników leczenia, ale zmusza również do dokonywania wyboru leku. Decyzja ta jest szczególnie istotna w...
Targeted therapies in neuroendocrine neoplasms
The primary treatment of gastrointestinal neuroendocrine tumors is surgery, and its extent depends on the clinical stage of cancer. In advanced disease medical therapy is used. One possible form of treatment is biologica...
Central venous catheters and complications in cancer patients
Vascular access has great importance in the treatment of patients submitted to prolonged chemotherapy. We report two patients with early and late complications related to the presence of a central venous catheter. The fi...
Targeted therapies for chronic myeloid leukemia and cardiovascular system
Morbidity of chronic myeloid leukemia is recorded in elderly population, in patients with coexisting significant risk factors for atherosclerosis and heart diseases. Molecularly targeted therapy, imatinib, dasatinib and...